Essential Premium

A Quick Windfall for Hedge Funds, Another Blow for a Biotech Company’s Early Backers

A private placement has delivered a 46 percent gain in under a week, but it’s small comfort to the investors who rode Solid Biosciences all the way down.

Seligman’s Paul Wick: Tesla’s Stock Will Sink in 2026

The tech specialist explains why the controversial electric-carmaker remains his largest short position.

Sponsored

How to Know if Your Nonprofit is Ready for an Endowment

A Surprising Winner in the Trump-Era Energy Landscape

Molecule Ventures’ carbon-focused strategy delivered a huge gain in 2025 as cap‑and‑trade markets tightened worldwide.

Related Content

RFK Jr.’s Leadership of HHS Weighs on Biopharma

Stephen Taub

Hedge Funds Featured Prominently in 2020 SPAC Boom

Stephen Taub

1270 Avenue of the Americas, Suite 1100

New York, NY 10020

 

© Institutional Investor, LLC. All material subject to strictly enforced copyright laws. Please read our Terms and Conditions and Privacy Policy before using the site. Institutional Investor is part of Delinian.

 

| Unsubscribe

LinkedIn
X (Twitter)
Bluesky
Instagram